Literature DB >> 16230378

Nox4 is critical for hypoxia-inducible factor 2-alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma.

Jodi K Maranchie1, Ye Zhan.   

Abstract

Inactivation of the von Hippel-Lindau tumor suppressor (VHL) is an early event in >60% of sporadic clear cell renal cell carcinoma (RCC). Loss of VHL E3 ubiquitin ligase function results in accumulation of the alpha-subunit of the hypoxia-inducible heterodimeric transcription factor (HIF-alpha) and transcription of an array of genes including vascular endothelial growth factor, transforming growth factor-alpha, and erythropoietin. Studies have shown that HIF-alpha can be alternatively activated by reactive oxygen species. Nox4 is an NADP(H) oxidase that generates signaling levels of superoxide and is found in greatest abundance in the distal renal tubules. To determine if Nox4 contributes to HIF activity in RCC, we examined the impact of Nox4 expression on HIF-alpha expression and transactivation. We report here that small inhibitory RNA (siRNA) knockdown of Nox4 in 786-0 human renal tumor cells expressing empty vector (PRC) or wild-type VHL (WT) results in 50% decrease in intracellular reactive oxygen species as measured by a fluorescent 2',7'-dichlorofluorescin diacetate assay, and >85% reduction in HIF2-alpha mRNA and protein levels by quantitative reverse transcription-PCR and Western blot analysis. Furthermore, expression of the HIF target genes, vascular endothelial growth factor, transforming growth factor-alpha, and Glut-1 was abrogated by 93%, 74%, and 99%, respectively, after stable transfection with Nox4 siRNA relative to nontargeting siRNA, as determined by quantitative reverse transcription-PCR. Thus, renal Nox4 expression is essential for full HIF2-alpha expression and activity in 786-0 renal tumor cells, even in the absence of functional VHL. We propose the use of Nox4 as a target in the treatment of clear cell RCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16230378      PMCID: PMC1459967          DOI: 10.1158/0008-5472.CAN-05-2105

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  A novel superoxide-producing NAD(P)H oxidase in kidney.

Authors:  A Shiose; J Kuroda; K Tsuruya; M Hirai; H Hirakata; S Naito; M Hattori; Y Sakaki; H Sumimoto
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

Review 2.  Cytokine therapy for metastatic renal cell carcinoma.

Authors:  R M Bukowski
Journal:  Semin Urol Oncol       Date:  2001-05

3.  Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth.

Authors:  Neville N C Tam; Ying Gao; Yuet-Kin Leung; Shuk-Mei Ho
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

Review 4.  Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression.

Authors:  Thomas Kietzmann; Agnes Görlach
Journal:  Semin Cell Dev Biol       Date:  2005 Aug-Oct       Impact factor: 7.727

Review 5.  Genetic disorders and renal cell carcinoma.

Authors:  Jodi K Maranchie; W Marston Linehan
Journal:  Urol Clin North Am       Date:  2003-02       Impact factor: 2.241

6.  Identification of renox, an NAD(P)H oxidase in kidney.

Authors:  M Geiszt; J B Kopp; P Várnai; T L Leto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

7.  HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.

Authors:  Stefano J Mandriota; Kevin J Turner; David R Davies; Paul G Murray; Neil V Morgan; Heidi M Sowter; Charles C Wykoff; Eamonn R Maher; Adrian L Harris; Peter J Ratcliffe; Patrick H Maxwell
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

8.  Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice.

Authors:  Marzia Scortegagna; Kan Ding; Yavuz Oktay; Arti Gaur; Frederick Thurmond; Liang-Jun Yan; Brett T Marck; Alvin M Matsumoto; John M Shelton; James A Richardson; Michael J Bennett; Joseph A Garcia
Journal:  Nat Genet       Date:  2003-11-09       Impact factor: 38.330

9.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.

Authors:  Jodi K Maranchie; James R Vasselli; Joseph Riss; Juan S Bonifacino; W Marston Linehan; Richard D Klausner
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

10.  Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth.

Authors:  Keiichi Kondo; William Y Kim; Mirna Lechpammer; William G Kaelin
Journal:  PLoS Biol       Date:  2003-12-22       Impact factor: 8.029

View more
  48 in total

1.  Myocardin-related Transcription Factor Regulates Nox4 Protein Expression: LINKING CYTOSKELETAL ORGANIZATION TO REDOX STATE.

Authors:  Matthew Rozycki; Janne Folke Bialik; Pam Speight; Qinghong Dan; Teresa E T Knudsen; Stephen G Szeto; Darren A Yuen; Katalin Szászi; Stine F Pedersen; András Kapus
Journal:  J Biol Chem       Date:  2015-11-10       Impact factor: 5.157

Review 2.  To breathe or not to breathe: the haematopoietic stem/progenitor cells dilemma.

Authors:  C Piccoli; F Agriesti; R Scrima; F Falzetti; M Di Ianni; N Capitanio
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 3.  Relationship between Volatile Anesthetics and Tumor Progression: Unveiling the Mystery.

Authors:  Bo Jiao; Chun Yang; Nian-Nian Huang; Ning Yang; Jia Wei; Hui Xu
Journal:  Curr Med Sci       Date:  2018-12-07

Review 4.  Therapeutic potential of NADPH oxidase 1/4 inhibitors.

Authors:  G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood
Journal:  Br J Pharmacol       Date:  2016-07-14       Impact factor: 8.739

Review 5.  NADPH oxidase-derived ROS and the regulation of pulmonary vessel tone.

Authors:  G Frazziano; H C Champion; P J Pagano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-16       Impact factor: 4.733

6.  Nuclear NADPH oxidase-4 associated with disease progression in renal cell carcinoma.

Authors:  Dharam Kaushik; Keith A Ashcraft; Hanzhang Wang; Karthigayan Shanmugasundaram; Pankil K Shah; Gabriela Gonzalez; Alia Nazarullah; Cooper B Tye; Michael A Liss; Deepak K Pruthi; Ahmed M Mansour; Wasim Chowdhury; Dean Bacich; Hao Zhang; Amanda L Watson; Karen Block; Denise O'Keefe; Ronald Rodriguez
Journal:  Transl Res       Date:  2020-05-31       Impact factor: 7.012

7.  NADPH oxidase NOX4 supports renal tumorigenesis by promoting the expression and nuclear accumulation of HIF2α.

Authors:  Jennifer L Gregg; Robert M Turner; Guimin Chang; Disha Joshi; Ye Zhan; Li Chen; Jodi K Maranchie
Journal:  Cancer Res       Date:  2014-04-22       Impact factor: 12.701

Review 8.  Regulation of NADPH oxidase in vascular endothelium: the role of phospholipases, protein kinases, and cytoskeletal proteins.

Authors:  Srikanth Pendyala; Peter V Usatyuk; Irina A Gorshkova; Joe G N Garcia; Viswanathan Natarajan
Journal:  Antioxid Redox Signal       Date:  2009-04       Impact factor: 8.401

Review 9.  Redox control of renal function and hypertension.

Authors:  Ravi Nistala; Adam Whaley-Connell; James R Sowers
Journal:  Antioxid Redox Signal       Date:  2008-12       Impact factor: 8.401

10.  Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice.

Authors:  Sulochana S Bhandarkar; Marisa Jaconi; Levi E Fried; Michael Y Bonner; Benjamin Lefkove; Baskaran Govindarajan; Betsy N Perry; Ravi Parhar; Jamie Mackelfresh; Allie Sohn; Michael Stouffs; Ulla Knaus; George Yancopoulos; Yvonne Reiss; Andrew V Benest; Hellmut G Augustin; Jack L Arbiser
Journal:  J Clin Invest       Date:  2009-07-13       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.